Clinical Trial Update: A Phase 2, Open-label Study of AMG 706 to Treat Subjects With Locally Advanced or Metastatic Thyroid Cancer [Phase 2]

View source ↗

Summary

Amgen completed a Phase 2 open-label trial of AMG 706 in patients with locally advanced or metastatic thyroid cancer. The study status is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Thyroid Cancer

Drugs mentioned

• AMG 706 (motesanib)

Snippet

Sponsor: Amgen | Conditions: Thyroid Cancer | Phase 2 | Status: COMPLETED